TFH lymphomas: the times they aza-changin'?

Abstract

In this issue of Blood, O’Connor and colleagues report a phase 1 study of romidepsin combined with oral azacytidine in patients with relapsed/refractory (R/R) lymphomas, including complete remissions among 3 patients with angioimmunoblastic T-cell lymphoma (AITL) and single patients with multiple other lymphoma subsets.